The Food and Drug Administration has approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections. The drug will be ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people.

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo. In clinical ...

Japanese women in their twenties were twice as likely to take extended sick leave as their male counterparts, a recent survey has found, prompting calls to health officials to pay more attention ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV WASHINGTON -- The U.S. has approved the world’s only twice-a-year shot to prevent HIV ...

An injectable HIV-1 capsid inhibitor, lenacapavir marks the first and only twice-yearly PrEP option available in the U.S. "Yeztugo could be the transformative PrEP option we've been waiting for ...

Báez, honored by teammates Tuesday for reaching 10 years of MLB service time, homered twice and helped power the Tigers to a 7-3 win over the Pittsburgh Pirates at Comerica Park.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U ...

By Apoorva Mandavilli The Food and Drug Administration on Wednesday approved a twice-yearly injection that provided a near-perfect shield against H.I.V. infection in clinical trials. The approval ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s ...